16 Abstract 17 Cancer affects millions of individuals worldwide. One shortcoming of traditional cancer 18 classification systems is that, even for tumors affecting a single organ, there is significant 19 molecular heterogeneity. Precise molecular classification of tumors could be beneficial in 20 personalizing patients' therapy and predicting prognosis. To this end, here we propose to 21 use molecular signatures to further refine cancer classification. Molecular signatures are 22 collections of genes characterizing particular cell types, tissues or disease. Signatures can 23 be used to interpret expression profiles from heterogeneous samples. Large collections of 24 gene signatures have previously been cataloged in the MSigDB database. We have 25 developed a web-based Signature Visualization Tool (SaVanT) to display signature 26 scores in user-generated expression data. Here we have undertaken a systematic analysis 27 of correlations between inflammatory signatures and cancer samples, to test whether 28 inflammation can differentiate cancer types. Inflammatory response signatures were 29 obtained from MsigDB and SaVanT and a signature score was computed for samples 30 associated with 7 different cancer types. We first identified types of cancers that had 31 high inflammation levels as measured by these signatures. The correlation between 32 signature scores and metadata of these patients (gender, age at initial cancer diagnosis, 33 cancer stage, and vital status) was then computed. We sought to evaluate correlations 34 between inflammation with other clinical parameters and identified four cancer types that 35 had statistically significant association (p-value < 0.05) with at least one clinical 36 characteristic: pancreas adenocarcinoma (PAAD), cholangiocarcinoma (CHOL), kidney 37 chromophobe (KICH), and uveal melanoma (UVM). These results may allow future 3 38 studies to use these approaches to further refine cancer subtyping and ultimately 39 treatment.
84 Mutations resulting in cancer may come about by a variety of sources, including 85 inflammation. Chronic inflammation has been shown to increase cancer risk (17, 18) by 86 causing tumor initiation, promotion, and metastatic progression (19) . Many 87 environmental causes of cancer are related to chronic inflammation. As many as 20% of 88 cancers are associated with chronic infection, 30% with tobacco smoking and inhaled 89 pollutants such as asbestos, and 35% with dietary factors (20) (21) (22) (23) . Chronic disease 90 exposing patients to inflammation are also associated with increased cancer risk.
91 Inflammatory bowel disease (i.e. ulcerative colitis and Crohn's disease) is associated with 92 an increased risk of colon adenocarcinoma (24), chronic pancreatitis is a significant risk 93 factor for pancreatic cancer (25), and chronic gastritis secondary to Helicobacter pylori 94 infection is associated with the majority of gastric cancer cases (26).
95
96 Several large consortia, such as The Cancer Genome Atlas (TCGA), provide tools and 97 data to study the molecular basis of cancer (11, 27) . The purpose of our study is to 98 understand molecular patterns related to inflammation. Although TCGA started out by 99 collecting only three cancer types -glioblastoma multiforme, lung, and ovarian cancers - 166 Results
168
Tumor Types
169
Hierarchical clustering was performed to group cancer subtypes by inflammatory 170 signature scores, and the three subgroups were determined by the dendrogram structure 171 resulting from the hierarchical clustering (Figure 1 ). Of the tumor types evaluated in our 172 study, we found that tumors in areas exposed to airways or gastrointestinal tracts,
173
including pancreatic, lung and esophageal cancer, tended to be more inflammatory.
174
Based on these results we selected seven tumor types with varying levels of inflammation 175 for further analysis (Figure 2 ). Of the 7 tumors chosen for analysis, the levels of 
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Once we compared the patient data to the inflammatory signatures, we found three 245 distinct groups of cancers: (1) those with high inflammation, (2) those with low 246 inflammation, and (3) those with both high and low levels of inflammation. We found 247 PAAD to be a member of the high inflammation group. This grouping is supported by 248 multiple studies associating pancreatic inflammation (pancreatitis) with the development 249 of pancreatic cancer (25, 32) . One of the cancers we found to be in the low inflammation 250 group was UVM. Melanomas are associated with environmental insults, such as 251 exposure to ultraviolet light. As such, we expect that inflammation is not necessarily 252 involved in the mechanism responsible for the development of skin cancer.
254
We believe that the gene expression data for these tumor types is heterogeneous across 255 individuals, with multiple subgroups of patients per type. As such, the inflammatory 256 signature presented in this first analysis is averaged across individuals, and that within these broad categories there may be subgroups of patients with high inflammation and 258 others with low inflammation. This suggests that patients with these cancers could 259 potentially benefit from further molecular subclassification.
261
In addition to correlating levels of inflammation with specific cancer types, we utilized 262 clinical metadata from individuals with 7 different types of distinct tumors and associated 263 this with molecular signatures derived from the web-based tool SaVanT. Molecular 264 signatures are gene collections with associated biological interpretations that can identify 265 genes upregulated in specific sample subsets compared to broader groups (15).
266
Signatures can be composed of genes associated with specific diseases. By performing a 267 comparison of metadata with molecular signatures, we sought to evaluate if there was 268 significant correlation between these values.
270
We found that four of the cancer types we evaluated (PAAD, CHOL, KICH, and UVM) 
299
In addition, although many cancer types fall into the high or low inflammation 300 classifications, there are others with a mixed inflammation signal. The ambiguity in this 301 group of cancer subtypes could arise from several sources and correcting for these sources may allow us to place these cancers into either the high-or low-inflammation 303 group. For example, the mixed signal could be due to the need to subclassify patients 304 even further for a particular cancer type. It is possible that some primary sites contain 305 several populations of samples -such as those from a different biopsy type (i.e., blood or 306 tumor sample). Determining these subgroups within the primary types would allow them 307 to be treated independently.
309
Finally, gene expression data is one of many biological layers potentially contributing to 310 cancer. Leveraging other levels of data, such as genome information, to identify 311 mutations within tumors and patients would greatly assist in determining and developing 312 therapies in a more personalized fashion for patients with different disease subtypes.
314
In summary, our study evaluated the association between inflammation signatures for 315 different tumor types. We found associations between levels of inflammation and tumor 316 types, and also found statistically significant relationships between patient metadata and 317 inflammation for four tumor types. We believe our results demonstrate potential clinical 318 utility in the continued establishment of personalized medicine and care for cancer 
